EUVIMEDEUVIMED entdecken
Systematische ÜbersichtÜbersichtsarbeit

Economic Evaluations of Orphan Drugs for Rare Kidney Diseases in Low- and Middle-Income Countries: A Bibliometric Systematic Review With Policy and Evidence Gaps Analysis

Mohammed Alfaqeeh, Auliya A Suwantika, Maarten J Postma, Rizkia Andicha Putra, Jasmine Rani Aisyah, Fima Perdani Rahayu, Lubna Farhana, Muhammad Ilyas, Shofuro Sholihah, Neily Zakiyah

Value in Health · 2026-04 · 29 (4) · 678-689

DOI: 10.1016/j.jval.2025.12.008 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Value in Health, 2026-04. Verfasst von Mohammed Alfaqeeh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral Program of Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Republic of Indonesia; Department of Pharmacology and Clinical P…. Hauptthemen laut MEDLINE: Orphan Drug Production, Developing Countries, Rare Diseases, Kidney Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 100 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: We conducted a systematic review and bibliometric analysis to explore the economic evaluation methods, outcomes, trends, and geographical distribution of orphan drugs for rare kidney diseases (RKDs) in low- and middle-income countries over the past decade. METHODS: A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies published from 2014 to 2024 were identified in PubMed and Scopus using keywords related to orphan drugs and RKDs. Eligible studies included full economic evaluations in low- and middle-income countries, reporting outcomes, such as incremental cost-effectiveness ratio per quality-adjusted life-years gained, life-years gained, and other clinical outcomes. Study quality was assessed using the Consolidated Health Economic Evaluation Reporting Standards checklist. Bibliometric analysis was performed with VOSviewer and Tableau. RESULTS: Among 406 identified studies, 16 met inclusion criteria. Cost-utility analysis was most common (88%), followed by cost-effectiveness (6%) and cost-minimization (6%). Most studies adopted a healthcare system (56%) or societal (19%) perspective. The majority used life-years and quality-adjusted life-years as outcome measures and considered direct medical costs, with 63% applying both probabilistic and deterministic sensitivity analyses. Reporting quality was high (87.5% rated as good), although gaps remained in heterogeneity, distributional effects, and funding disclosure. Overall, 63% found orphan drugs for RKDs cost-effective. Bibliometric analysis highlighted themes such as "cost-effectiveness," "advanced renal cell carcinoma," and "nivolumab." Geographically, 67% of studies were conducted in China. CONCLUSIONS: This review unexpectedly found that many studies identified orphan drugs for RKDs as cost-effective, despite their traditionally high costs. Future evaluations should refine methods to better capture long-term value and affordability in low- and middle-income countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Orphan Drug ProductionDeveloping CountriesRare DiseasesKidney DiseasesHumansCost-Benefit AnalysisQuality-Adjusted Life YearsBibliometricsEvidence Gaps

Stichwörter der Autor:innen

affordabilityeconomic evaluationorphan drugsrare kidney diseasesvisualization

Autor:innen und Institutionen

  • Doctoral Program of Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Republic of Indonesia; Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Republ…
  • Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Republic of Indonesia; Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung,…
  • Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Republic of Indonesia; Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, T…
  • Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Republic of Indonesia.

Zitieren

APA

Alfaqeeh, M., Suwantika, A. A., Postma, M. J., Putra, R. A., Aisyah, J. R., Rahayu, F. P., Farhana, L., Ilyas, M., Sholihah, S., & Zakiyah, N. (2026). Economic Evaluations of Orphan Drugs for Rare Kidney Diseases in Low- and Middle-Income Countries: A Bibliometric Systematic Review With Policy and Evidence Gaps Analysis. Value in Health, 29(4), 678-689. https://doi.org/10.1016/j.jval.2025.12.008

Vancouver

Alfaqeeh M, Suwantika AA, Postma MJ, Putra RA, Aisyah JR, Rahayu FP, et al. Economic Evaluations of Orphan Drugs for Rare Kidney Diseases in Low- and Middle-Income Countries: A Bibliometric Systematic Review With Policy and Evidence Gaps Analysis. Value in Health. 2026;29(4):678-689. doi:10.1016/j.jval.2025.12.008

BibTeX
@article{Alfaqeeh2026,
  author = {Alfaqeeh, Mohammed and Suwantika, Auliya A and Postma, Maarten J and Putra, Rizkia Andicha and Aisyah, Jasmine Rani and Rahayu, Fima Perdani and Farhana, Lubna and Ilyas, Muhammad and Sholihah, Shofuro and Zakiyah, Neily},
  title = {Economic Evaluations of Orphan Drugs for Rare Kidney Diseases in Low- and Middle-Income Countries: A Bibliometric Systematic Review With Policy and Evidence Gaps Analysis},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {4},
  pages = {678--689},
  doi = {10.1016/j.jval.2025.12.008}
}
Kostenlos starten →